$REGN Company News Regeneron skids on shortfall in

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 4:05 AM

$REGN Company News

Regeneron skids on shortfall in Eylea sales 11:15 a.m. Nov. 4, 2014 - Russ Britt
Regeneron Pharmaceuticals shares rise 8% 8:31 a.m. Oct. 17, 2014 - Sue Chang
10 rock-solid stocks for conservative investors 8:51 a.m. Sept. 17, 2014 - Philip van Doorn
S&P 500 nails the breakout point 9:35 a.m. Sept. 8, 2014 - Michael Ashbaugh
Regeneron shares run up 4.8% to lead S&P 500 gainers 8:34 a.m. Sept. 2, 2014 - Tomi Kilgore
Small health companies see large gains on a big earnings day 4:34 p.m. July 30, 2014 - Russ Britt
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 3:26 p.m. July 30, 2014 - Sue Chang
Edwards, Hospira rise as health-care companies see strong earnings 12:08 p.m. July 30, 2014 - Russ Britt
Regeneron shares jump after cholesterol drug meets test goals 10:16 a.m. July 30, 2014 - Russ Britt
Regeneron Pharmaceuticals jumps 7.7% 8:32 a.m. July 30, 2014 - Sue Chang
Dow ends at record high close but still shy of 17,000: Stock market live blog recap 3:04 p.m. July 1, 2014 - blogs.marketwatch.com
Twitter gains on new CFO; GM sales up in June 1:29 p.m. July 1, 2014 - Sue Chang
Oracle slides on disappointing results; CarMax soars 3:17 p.m. June 20, 2014 - Sue Chang
Maybe Amazon will unveil a toaster today 7:08 a.m. June 18, 2014 - Marek Fuchs
Twitter rallies ahead of earnings; 3D Systems retreats 2:49 p.m. April 29, 2014 - Sue Chang
Intuitive Surgical slumps; Facebook extends rally 2:41 p.m. April 9, 2014 - Sue Chang
44 stocks on takeover target radar: Morgan Stanley 11:48 a.m. March 25, 2014 - blogs.marketwatch.com
First Solar, H-P, Symantec are stocks to watch 3:16 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 2:07 p.m. March 21, 2014 - Sue Chang
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 2:51 p.m. March 11, 2014 - blogs.marketwatch.com

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Nov. 14, 2014 - Zacks.com
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals 7:02 a.m. Nov. 13, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:25 p.m. Nov. 12, 2014 - TheStreet.com
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog 11:00 a.m. Nov. 12, 2014 - Zacks.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14) 5:20 a.m. Nov. 12, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names 8:59 p.m. Nov. 11, 2014 - TheStreet.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN) 9:51 a.m. Nov. 11, 2014 - TheStreet.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: VZ, MRK, REGN 10:59 a.m. Nov. 10, 2014 - TheStreet.com
Regeneron updates guidance after Q3 results 11:09 a.m. Nov. 6, 2014 - Seeking Alpha
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way 11:24 a.m. Nov. 5, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
Jazz Beats And Raises Views; Regeneron Misses In Q3 6:02 p.m. Nov. 4, 2014 - Investors Business Daily
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog 4:30 p.m. Nov. 4, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript 4:16 p.m. Nov. 4, 2014 - TheStreet.com
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter 9:51 a.m. Nov. 4, 2014 - Investors Business Daily

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma 1:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Regeneron Reports Third Quarter 2014 Financial and Operating Results 6:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter 9:15 a.m. Nov. 3, 2014 - PR Newswire - PRF
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent 9:20 a.m. Oct. 23, 2014 - PR Newswire - PRF
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma 9:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study 7:00 a.m. Oct. 17, 2014 - PR Newswire - PRF
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year 2:00 p.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments 8:30 a.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014 4:01 p.m. Oct. 15, 2014 - PR Newswire - PRF
Critical Alerts For ITT Education, EOG Resources, Mobileye NV, CBS and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz 9:15 a.m. Oct. 7, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) 4:58 p.m. Oct. 6, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 1:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics 9:20 a.m. Sept. 25, 2014 - PR Newswire - PRF
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan 2:30 a.m. Sept. 22, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema 7:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Critical Alerts For Rocket Fuel, General Motors, International Business Machines, Google and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Sept. 8, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...